2023 Partners

Proud To Partner With:

antaros logo

Antaros Medical

Expertise Partner

Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies.
Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have
helped our customers to solve complex problems to empower confident decision-making at every stage of clinical drug
development, from small mechanistic studies to large scale studies. Disease areas: CV, renal & metabolic diseases and

Find out more at:

repair biotech

Repair Biotechnologies

Expertise Partner

Repair Biotechnologies is a preclinical biotech that develops gene therapies to reverse conditions such as NASH and
atherosclerosis, in which pathology is driven in large part by a cytotoxic excess of intracellular free cholesterol. Enzymatic
clearance of this toxic excess cholesterol has been shown to produce a rapid, safe, and sizable improvement in disease biomarkers and histology in animal models of NASH and atherosclerosis.

Find out more at:

Screenshot 2023-10-26 123334


Hosting Partner

HepQuant develops non-invasive, quantitative liver function tests. HepQuant has implemented the SHUNT test in over 35 clinical trials, the majority being MASH. Compartmental modeling and machine learning has produced next generation HepQuant technology which HepQuant is offering for use in clinical trials (SHUNT and DuO tests). The HepQuant DuO Test, a Laboratory Developed Test (LDT), is simply a single oral dose of stable isotope-labeled cholate followed by two blood draws. This test accurately produces a DSI score and estimates portal-systemic shunting, delivering both parameters with high reproducibility. The company plans to launch the HepQuant DuO Test to hepatologists in 4Q2023.

Find out more at:

nordic bioscience

Nordic Bioscience

Program Partner

Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine
our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials and provide value for patients in a diagnostic setting.

Find out more at:


Summit Clinical Research

Hosting Partner

Summit is the world’s leading Integrated Research Organization (IRO) in the field of hepatology research. Established in 2018, Summit’s foundations are deeply rooted in expanding the understanding of liver disease from onset of diagnosis through management of the disease process. Summit is an organization committed to company culture, employee retention, and therapeutic expertise, and quality. Summit delivers a full spectrum of study oversight, enrollment, and site enrichment services, utilizing strategic partnerships and sites from within our network. We have a passion for supporting drug development therapy in chronically ill patient populations and are well renowned for our leadership in hepatology.

Find out more at:

AGA Horizontal Logo - Color


Hosting Partner


Find out more at:




Exhibition Partner

E-Scopics develops a dematerialized ultrasound platform to democratize the use of ultrasound by healthcare professionals. The low-power, ultrafast capabilities of the platform allow the development of premium features in a bedside ultraportable form factor. The company’s first cleared product, “Hepatoscope”, is a dedicated digital “echoscope” that helps assess non-invasively chronic liver diseases, and especially MASLD-MASH, using ultrasound-based quantitative parameters related to liver steatosis and fibrosis. Hepatoscope ultrasound-as-a-service is commercialized via a subscription model.

Find out more at:



MLM Medical Labs

Exhibition Partner


Find out more at:




Exhibition Partner


Find out more at:


logo echosens and claim_gradient (1)


Exhibition Partner


Find out more at:




Exhibition Partner


Find out more at:




Innovation Partner


Find out more at:




Event Partner

Physiogenex provides preclinical in vivo and ex vivo CRO services with 20 years of expertise in evaluating drugs targeting metabolic diseases such as obesity, diabetes, MASH, MetALD, liver/lung/kidney fibrosis, diabetic nephropathy, neuropathy, inflammatory bowel diseases and microbiome, cardiovascular complications, dyslipidemia and atherosclerosis. Our unique preclinical models have been published in >25 high impact factor journals and presented in >100 international scientific conferences. We help +100 companies worldwide (including 10 of top 15 international biotech and pharma companies) with a 97.5% customer satisfaction rate over the last 3 years.

Find out more at:




Event Partner

Gubra is a specialized full-service CRO and peptide drug/target discovery partner. Gubra’s main focus is on preclinical studies and peptide-based drug discovery within obesity, diabetes and associated late-stage complications, notably metabolic dysfunction-associated steatohepatitis (MASH, formerly known as non-alcoholic steatohepatitis or NASH). Gubra is industry-leading in translational animal models of obesity, diabetes, MASH and MASH-driven hepatocellular cancer. We conduct comprehensive drug efficacy studies combining in vivo metabolic profiling, advanced histology, 3D whole-brain imaging and RNA sequencing to evaluate drug candidates. Our automated AI-based pipeline enables objective, fast-track and, high-quality analysis of pivotal clinical therapeutic endpoints in our preclinical disease models.

Find out more at:

Want to See Your Logo Here?

MicrosoftTeams-image (40)